Targeting TGFβR2‐mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer
Huocong Huang(Southwestern Medical Center), Rolf A. Brekken(Southwestern Medical Center)
Cited by 87
Related Papers
Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution
|JCI Insight|2019|281
Sitravatinib potentiates immune checkpoint blockade in refractory cancer models
|JCI Insight|2018|111
Phosphorylation of Akt and ERK1/2 Is Required for VEGF-A/VEGFR2-Induced Proliferation and Migration of Lymphatic Endothelium
|PLoS ONE|2011|99
Losartan Slows Pancreatic Tumor Progression and Extends Survival of SPARC-Null Mice by Abrogating Aberrant TGFβ Activation
|PLoS ONE|2012|77
Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution
|bioRxiv (Cold Spring Harbor Laboratory)|2019|75